This could be due to the involvement of compensatory mechanisms as reported
for STAT 3 in response to dasatinib in head and neck cancer and mesothelioma. To decide regardless of whether EBIP reaches the tumor, we analyzed the tissues for the presence of EBIP. Certainly, we observed substantial expression of EBIP in the tumors of EBIP handled mice. To figure out whether or not inhibition of tumor development in SCID mice could be the end result of increased apoptosis, we conducted TUNEL assay and examined PARP cleavage in the tumors.
